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Dear Editor,
Dengue is an old viral disease that has re-emerged in 
recent time. It is regarded as a tropical fever infection 
placing more than 2 billion of the world's population 
[1]at high risk.  The lack of potent antiviral drugs and 
availability of dengue vaccine in less than 5 
countries have placed about 500,000 individuals 
(mainly children) being hospitalized with severe 
dengue every year. This has caused tremendous 
socioeconomic losses for both households and 
[1]nations.  
In 1960s, Dengue virus was first isolated in Africa at 
[2]Ibadan.  Several reports have consistently shown 
that all dengue virus serotypes and its vectors (Aedes 
spp) are endemic in Nigeria. The demonstration of 
dengue neutralizing antibodies in monkeys, and 
galagos suggest the occurrence of a forest cycle of 
[3] dengue in Nigeria. Fagbami et al demonstrated that 
17 flavivirus neutralizing antibody-positive sera 
contained infection-enhancing antibodies to dengue. 
[4] In that report heterologous infection-enhancing 
antibody titers were lower than the homologous 
[4]ones.  In another study in Oyo state, involving mild 
febrile illness, 81% of the patients examined had 
[5]antibody to dengue type-1.  In another study 
involving four ecological zones in Nigeria, the 
highest percentage (63%) of dengue neutralizing 
antibody was observed in the rain forest zone and 
[6]plateau zone showed lowest (10%). 
In addition, a high prevalence of antibody to DEN-2 
[7]has been reported in Kainji Lake area of Nigeria.  
In 2009, Baba and Talle detected DENV 1 & 4 in 
serum sample of febrile patients as well as from 
[8]mosquitoes identified as Aedes aegypti.  In 2013, 
Idris et al, reported that out of 256 sera from febrile 
patients analyzed using microneutralization test, 26 
(10.1%) had neutralizing antibodies to DENV-3 
[9]virus.  Thereafter, few ELISA-based studies were 
conducted all over Nigeria with IgG seropositivity 
[10]ranging between 45 to 65%. . In 2017, Nasir et al 
and Kolawole et al separately reported acute dengue 
cases among febrile patients at Abuja and Ilorin, 
[11, 12]respectively. 
The transmission of dengue is climate sensitive for 
several reasons: mosquitoes require standing water 
to breed and a warm ambient temperature is critical 
to adult feeding behavior, the mortality rate of larval 
development and as well as speed of virus 
[13]replication.  In countries where transmission does 
routinely occur, short-term changes in weather, 
particularly temperature, precipitation, and 
humidity, are often correlated with dengue 
[13]incidence.  Some studies on relationship between 
climatic change and dengue showed possible 
increase in dengue virus transmission due to higher 
[14]temperatures, humidity, and precipitation.   In a 
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related study, it was found that the monthly dengue 
virus activity was highest during the rainy season of 
the months of June, July, and August and lowest in 
the dry months of January and February 
[15]respectively. 
Antibody-Dependent Enhancement mechanism 
(ADE) has dominated as the explanatory model for 
severe dengue disease in secondary infections. 
However, evidence for ADE in humans is indirect 
[16] and controversial results against ADE exist. Many 
parts of the world have become hyperendemic, 
implying that all four serotypes of DENV co-
circulate in the same country, with the consequence 
[17]that secondary infections are common scenarios.  
Epidemiological data indicated that not all 
secondary infections cause DHF/DSS, and that there 
are even cases of tertiary and quaternary DENV 
[18]infections.  In Cuba, 17.5% of the total DHF 
dengue cases were caused by third or fourth 
[17]infections. 
The severity of DENV infection is modulated by 
multiple risk factors such as age, sex, viral serotype 
/genotype, host genetic background, and non-
primary dengue virus infection by heterologous 
serotypes. Apart from the influence of viral genetic 
profile, the host's genetic background with varying 
polymorphisms has important consequences for 
[19]severe dengue.  Evidence of the host's genetic 
importance has been derived from Cuban dengue 
epidemics where a reduced risk for DHF/DSS was 
observed in those with an African ancestry 
compared to those with European ancestry. The 
Cuban observations coincide with the low 
susceptibility to DHF reported in African and Black 
[19]Caribbean populations.  It is interesting that 
despite the circulation of dengue virus in many 
African nations, there are only sporadic reports of 
DHF. 
A significantly higher frequency of HLA class I 
alleles A*31 and B*15 have been found in Cuban 
individuals with symptomatic DENV infection 
compared to asymptomatic controls, who showed an 
elevated frequency of HLA II alleles DRB1*07 and 
[19]DRB1*04.  This shows that polymorphisms in 
HLA class I gene place dengue infected individuals 
to higher risk of disease severity than those without 
polymorphisms. Genetic polymorphism that confers 
protection against development of severe dengue 
have also been recently described in mannose 
binding lectin-2 (MBL2) gene and HLA class II. 
Polymorphism in MBL2 gene has been shown to be 
associated with thrombocytopaenia and an increased 
risk for developing DHF. Findings have shown that 
10% of Caucasian and mongoloids have wild type of 
this gene and non from the black race. This might 
also be another explanation for racial susceptibility 
[20]to dengue severity.  
Effective vector control measures are 
the sole weapon against dengue. Hence, educational 
and adherence to preventive measures should focus 
on minimizing people susceptibility of acquiring 
dengue through barrier from vector breeding sites 
and bite on humans.
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